Immunogenicity & reactogenicity of a recombinant HPV6 fusion protein vaccine adjuvanted with monophosphoryl lipid A.
Thompson
S
S
Cantab Pharmaceuticals, Cambridge.
Davies
M
M
O'Neill
T
T
Holding
F
F
Mann
A
A
Martin
G
G
Varley
C
C
Watts
M
M
Beech
J
J
Thompson
S J
SJ
Leesman
G
G
Ulrich
T
T
D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D004655:Emulsions; D006801:Humans; D008050:Lipid A / Q000031:analogs & derivatives*; D008297:Male; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control; D011817:Rabbits; D011993:Recombinant Fusion Proteins; D014412:Tumor Virus Infections / Q000517:prevention & control; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004655:Emulsions; D008050:Lipid A; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D000536:Aluminum Hydroxide; C048436:monophosphoryl lipid A